Back to Authors

Ghatta, Srinivas

A5072677644 | I4210103816

Mayo Clinic

Allogene Therapeutics (United States)

Citations 1

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4620-4622

10.1182/blood-2022-158231